Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
The development of COVID-19 treatment
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
VV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19
Z Cao, W Gao, H Bao, H Feng, S Mei… - … England Journal of …, 2023 - Mass Medical Soc
Background Nirmatrelvir–ritonavir has been authorized for emergency use by many
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …
[HTML][HTML] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
B Killingley, AJ Mann, M Kalinova, A Boyers… - Nature Medicine, 2022 - nature.com
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan… - Nature, 2023 - nature.com
Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …
demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …
[HTML][HTML] Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
H Pan, R Peto, AMH Restrepo, MP Preziosi… - The Lancet, 2022 - Elsevier
Summary Background The Solidarity trial among COVID-19 inpatients has previously
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …
Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19
J Hammond, H Leister-Tebbe, A Gardner… - … England Journal of …, 2022 - Mass Medical Soc
Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …
[HTML][HTML] Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
L Vangeel, W Chiu, S De Jonghe, P Maes, B Slechten… - Antiviral research, 2022 - Elsevier
We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524,
molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor …
molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023
World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)
A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …
COVID-19. Outline the latest treatments available in the management of COVID-19 …